2025 Annual Individual Financial Results: Revenue Slightly Up (+0.3%) but Net Profit Plunges 39.5%
-
Sales: KRW 309.1 billion, up 0.3% YoY
-
Operating profit: KRW 26.9 billion, down 15% YoY
-
Pre-tax profit: KRW 21.8 billion, down 50.1% YoY
-
Net profit: KRW 23.7 billion, down 39.5% YoY
-
Reasons: increased cost from higher product sales proportion, base effect from prior year tax refund
-
Financial position: Total assets KRW 470.2 billion, liabilities KRW 180.1 billion, equity KRW 290.1 billion
-
Unaudited, subject to change.
KOSPI Filing Information
-
Filing: Change in Sales or Profit Structure of 30% (15% for Large Corporations) or More
-
Company: Samjin Pharmaceutical (005500)
-
Submission: Samjin Pharmaceutical Co., Ltd.
-
Receipt: 02-02-2026
-
Under KRX KOSPI Market Division